The non-invasive prenatal testing market is expected to grow at a CAGR of 17.1% from 2019 to 2027 to reach $13.14 billion by 2027.
With the emergence of innovative diagnostic and screening techniques, several methods of genetic testing are gaining popularity. These include carrier testing, preimplantation genetic diagnosis / screening (PGD / PGS), non-invasive prenatal testing (NIPT), paternity testing, and newborn screening. Technological advancements in the healthcare industry such as wearable healthcare devices, sequencing technologies, regenerative medicine, and genomic technologies, supported by breakthroughs in the field of genome sequencing and molecular research have opened new and promising pathways to combat genetic diseases and reduce the overall global economic burden.
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5068
Among the innumerable advancements witnessed by the industry, non-invasive prenatal testing stands as one of the most distinctive technologies in curbing the concerns related to genetic diseases. NIPT a novel genetic screening method based on the analysis of cell-free fetal deoxyribose nucleic acid (cff-DNA) in the maternal plasma is considered as a valuable test for pregnant women, which provides early diagnosis of genetic disorders in fetus.
Further, advancements in genome sequencing technologies have reduced the turnaround time and lowered complexities associated with diagnosis. NGS technology provides several avenues to develop non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. This is driving several companies to invest in research and development of NGS-based NIPT products and develop innovative solutions for the market. For instance, in January 2019, Yourgene Health plc (U.K.) launched the Sage 32 plex test which uses Thermo Fisher’s Ion Torrent sequencing technology to detect placental cff-DNA in a maternal blood sample. Similarly, in September 2018, Yourgene Health formerly known as Premaitha Health plc. (U.K.) partnered with Illumina Inc. (U.S.) to use the Illumina’s sequencing technology for the NIPT test developed by Premaitha.
The growth in the overall NIPT market is majorly driven by factors like shifting trend towards childbirth at an advanced maternal age, increasing prevalence of chromosomal abnormalities, availability of reimbursement for NIPT, and development of advanced technologies for non-invasive parenteral testing. However, the high cost of the non-invasive prenatal screening techniques hinders the growth of this market.Some of the key players operating in the global non-invasive prenatal testing market are Illumina, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.S.), PerkinElmer Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Eurofins LifeCodexx (Germany), Natera, Inc. (U.S.), Igenomix S.L (Spain), Laboratory Corporation of America Holdings (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), and Yourgene Health plc (U.K.).
Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5068
No comments:
Post a Comment